<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6657237</article-id><article-id pub-id-type="publisher-id">36990</article-id><article-id pub-id-type="doi">10.5114/aoms.2019.86061</article-id><article-categories><subj-group subj-group-type="heading"><subject>State Of the art paper</subject></subj-group></article-categories><title-group><article-title>Mitochondria in migraine pathophysiology &#x02013; does epigenetics play a role?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fila</surname><given-names>Micha&#x00142;</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Paw&#x00142;owska</surname><given-names>El&#x0017c;bieta</given-names></name><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Blasiak</surname><given-names>Janusz</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib></contrib-group><aff id="aff0001"><label>1</label>Department of Neurology, Polish Mother Memorial Hospital, Research Institute, Lodz, Poland</aff><aff id="aff0002"><label>2</label>Department of Orthodontics, Medical University of Lodz, Lodz, Poland</aff><aff id="aff0003"><label>3</label>Department of Molecular Genetics, University of Lodz, Lodz, Poland</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Micha&#x00142; Fila, Department of Neurology, Polish Mother Memorial Hospital, Research Institute, 188 Rzgowska St, 93-543 Lodz, Poland. Phone: +48 42 271 13 71, Fax: +48 42 271 13 70.E-mail <email xlink:href="michalfila@poczta.onet.pl">michalfila@poczta.onet.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2019</year></pub-date><volume>15</volume><issue>4</issue><fpage>944</fpage><lpage>956</lpage><history><date date-type="received"><day>12</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>06</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2019 Termedia &#x00026; Banach</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><p>The approximately three times higher rate of migraine prevalence in women than men may result from the mitochondrial transmission of this disease. Studies with imaging techniques suggest disturbances in mitochondrial metabolism in specific regions of the brain in migraine patients. Migraine shares some clinical features with several mitochondrial diseases and many other disorders include migraine headaches. Epigenetic regulation of mitochondrial DNA (mtDNA) is a matter of debate and there are some conflicting results, especially on mtDNA methylation. Micro RNAs (miRNAs) and long-noncoding RNA (lncRNAs) have been detected in mitochondria. The regulation of the miRNA-lncRNA axis can be important for mitochondrial physiology and its impairment can result in a disease phenotype. Further studies on the role of mitochondrial epigenetic modifications in migraine are needed, but they require new methods and approaches.</p></abstract><kwd-group><kwd>mitochondrial DNA</kwd><kwd>DNA methylation</kwd><kwd>micro RNA</kwd><kwd>long non-coding RNA</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Migraine belongs to the commonest disorders worldwide and it significantly lowers quality of life and work productivity, resulting in a high burden for patients, society and employers. Annual migraine-associated cost in the US is about USD 80 billion [<xref rid="cit0001" ref-type="bibr">1</xref>].</p><p>Migraine prevalence varies from continent to continent and from country to country, but in general it is relatively high as compared with many other chronic diseases. That prevalence depends on age and can be approximately three times higher in women than in men (<xref ref-type="fig" rid="f0001">Figure 1</xref>). Hover, the peak of migraine incidence is observed in adolescence. It is a complex disease affecting several regions of the brain, inducing vascular dysfunction, cranial vasodilation and release of some neuromodulators, such as dopamine [<xref rid="cit0002" ref-type="bibr">2</xref>]. Current migraine therapies are effective only in a proportion of patients and studies on new therapeutic targets are needed.</p><fig id="f0001" position="float"><label>Figure 1</label><caption><p>Worldwide migraine prevalence in 2016 according to WHO (both sexes, all ages). Inset &#x02013; prevalence by age and sex (<ext-link ext-link-type="uri" xlink:href="https://vizhub.healthdata.org/gbd-compare/">https://vizhub.healthdata.org/gbd-compare/</ext-link>)</p></caption><graphic xlink:href="AMS-15-36990-g001"/></fig><p>Recurrent episodes of headache are the hallmark of migraine and they are usually associated with an array of other symptoms, including nausea, vomiting, photo- and phonophobia, visual disturbances and others. According to the International Headache Society, two main clinical subtypes of migraine can be considered: migraine with aura (MA) and without aura (MO). Other rarer type of migraine are basilar-type migraine (BTM) and familial hemiplegic migraine (FHM). Aura occurs in about one third of all migraine patients and includes mainly visual symptoms, but also aphasia, dyschromatopsia, prosopagnosia, ideational apraxia, alien hand syndrome and proper name anomia [<xref rid="cit0003" ref-type="bibr">3</xref>].</p><p>The pathophysiology of migraine is not fully known and there were two opposite theories on the cause and nature of migraine attacks &#x02013; the vascular and the neuronal theory, which were then combined into the neurovascular theory [<xref rid="cit0004" ref-type="bibr">4</xref>]. Several other theories can be considered, including the hypothalamus theory, the serotonin theory, the depolarization theory and others. Migraine is a complex disease with the phenotype determined by the interaction between genetic, environmental and life-style factors. The pathogenesis of migraine is determined by phenomena occurring in the sensory cortex of the brain and/or the brain stem [<xref rid="cit0005" ref-type="bibr">5</xref>].</p><p>It is commonly accepted, although not firmly evidenced, that migraine is a threshold disease, released by a brain-related trigger [<xref rid="cit0006" ref-type="bibr">6</xref>&#x02013;<xref rid="cit0009" ref-type="bibr">9</xref>]. Such migraine trigger and the wave of depolarization induce the activation of neurons of the trigeminal nerve, which release chemical substances inducing the dilation of blood vessels and inflammation, which directly cause migraine headache (<xref ref-type="fig" rid="f0002">Figure 2</xref>). Cortical spreading depression (CSD), a wave of neuronal hyperexcitability followed by suppression of neural activity, may be responsible for disturbances occurring in MA [<xref rid="cit0010" ref-type="bibr">10</xref>].</p><fig id="f0002" position="float"><label>Figure 2</label><caption><p>A migraine trigger (yellow thunder) acts on the nucleus (light blue oval) of the trigeminal nerve (dark blue) and activates it. Resulting waves of depolarization (black broken arrows) move along the nerve and reach the cortex, inducing cortical spreading depression (CSD). This results in an inflammation- like state and release of inflammatory neurotransmitters, which induce dilation of brain blood vessels (red), which in turn evokes migraine headache. This figure does not correspond to actual anatomical relationships within the brain</p></caption><graphic xlink:href="AMS-15-36990-g002"/></fig><p>Early magnetic resonance imaging (MRI) studies revealed a low level of high energy phosphates in the brain of migraine patients, suggesting defects in brain energy metabolism in migraine [<xref rid="cit0011" ref-type="bibr">11</xref>]. These studies had several limitations. First of all they did not provide information on physiological dysfunctions associated with observed effects. Currently, more detailed imaging studies on migraine mechanisms are conducted with positron emission tomography (PET) and functional MRI (fMRI) (see [<xref rid="cit0012" ref-type="bibr">12</xref>] for review). Studies with these techniques showed that repeated migraine attacks modified metabolism in specific regions of the brain involved in sensory and pain processing, including the bilateral insula, premotor and secondary somatosensory cortex (<xref ref-type="fig" rid="f0003">Figure 3</xref>). These studies reported ATP depletion due to a deficient mitochondrial metabolism in brains of migraine patients [<xref rid="cit0013" ref-type="bibr">13</xref>]. These studies suggest a significant role of mitochondria in the pathophysiology of migraine.</p><fig id="f0003" position="float"><label>Figure 3</label><caption><p>Repeated migraine attacks are associated with a metabolic modification of specific brain regions including premotor (blue) and secondary (brown) somatosensory cortex. Metabolic modifications in these regions result in impaired mitochondrial functions leading to depleted ATP production</p></caption><graphic xlink:href="AMS-15-36990-g003"/></fig></sec><sec id="sec2"><title>Mitochondria &#x02013; an important player in migraine pathogenesis</title><p>Approximately three times higher frequency of migraine prevalence in females than males suggests either X-linked form of this disease, the mitochondrial transmission of another form of it, or both. However, if changes in mitochondria can contribute to the pathogenesis of migraine, not only mtDNA, but also the nuclear genes encoding mitochondrial components and regulating their functions may play a role.</p><p>Mitochondrial dysfunction can be associated with increased neuronal excitability resulting in increased susceptibility to migraine [<xref rid="cit0014" ref-type="bibr">14</xref>]. Any mitochondrial impairment in the brain likely leads to a deficit in mitochondrial energy, which in turn can be a migraine trigger. Some positive results on the influence of a high-fat and low-carbohydrate (ketogenic) diet on migraine and epilepsy course seem to support this assumption because such a diet stimulates mitochondrial metabolism [<xref rid="cit0015" ref-type="bibr">15</xref>, <xref rid="cit0016" ref-type="bibr">16</xref>]. Further support is provided by the observation of the protective action of riboflavin and the Q10 coenzyme, both enhancing the function of the mitochondrial electron transport system (ETS, respiratory chain) against migraine [<xref rid="cit0017" ref-type="bibr">17</xref>&#x02013;<xref rid="cit0019" ref-type="bibr">19</xref>].</p><p>A cross-sectional questionnaire-based study on 85 patients with various mitochondrial diseases (MDs) resulted in a higher frequency of headaches in this group compared to individuals without clinically detected mitochondrial impairments [<xref rid="cit0020" ref-type="bibr">20</xref>]. The highest prevalence of tension-type headache (TTH) was observed, but the prevalence of migraine and probable migraine was only slightly lower. This study was supported by research showing a higher prevalence of migraine in individuals with MDs than in the general population [<xref rid="cit0021" ref-type="bibr">21</xref>]. Stratification of migraine cases into MD types suggested that migraine might not be a phenotypic feature of a particular MD, but might instead be linked with a common susceptibility of the central nervous system to some factors, likely associated with defects in ETS accompanying that MD.</p></sec><sec id="sec3"><title>Riboflavin as well as MELAS and other mitochondrial diseases link migraine with mitochondria</title><p>Riboflavin (vitamin B<sub>2</sub>) belongs to the B complex vitamins playing an important role as coenzymes in many flavoprotein enzyme reactions. It occurs in two active forms, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which are important for vital mitochondrial processes, including metabolism of amino acids, purines and fatty acids as well as the redox reaction [<xref rid="cit0022" ref-type="bibr">22</xref>]. Riboflavin deficiency is a world-wide problem and it has been shown to improve the clinical picture of several mitochondrial diseases, including complex I and II-associated myopathies [<xref rid="cit0023" ref-type="bibr">23</xref>&#x02013;<xref rid="cit0029" ref-type="bibr">29</xref>].</p><p>As brain metabolism is disturbed in migraine and riboflavin ameliorates the functioning of ETS, its evaluation in clinical trials as a prophylactic agent is justified [<xref rid="cit0030" ref-type="bibr">30</xref>]. Riboflavin prophylaxis was effective in migraine in adults, which may follow from the general neuroprotective effect of this compound [<xref rid="cit0030" ref-type="bibr">30</xref>&#x02013;<xref rid="cit0033" ref-type="bibr">33</xref>]. Di Lorenzo <italic>et al</italic>. reported that migraine patients with non-H mtDNA haplogroup responded more frequently to riboflavin than patients with the H group [<xref rid="cit0034" ref-type="bibr">34</xref>]. On the other hand, the frequency of riboflavin non-responders was higher in the H group. There were no differences between MA and MO patients in riboflavin responsiveness. These studies suggest that the efficacy of riboflavin therapy can depend on the patient genotype.</p><p>Riboflavin decreased the frequency of headache attacks and their duration in a randomized, controlled trial performed by Shoenen <italic>et al.</italic> [<xref rid="cit0035" ref-type="bibr">35</xref>]. These results were confirmed in another clinical trial performed by Rahimdel <italic>et al.</italic>, who also observed a decrease in frequency of headache attacks [<xref rid="cit0036" ref-type="bibr">36</xref>]. Several other clinical trials with riboflavin singly or in combination with other agents both in adult and adolescent migraine patients brought positive results &#x02013; more details are presented in an excellent review by Thompson and Saluja [<xref rid="cit0030" ref-type="bibr">30</xref>].</p><p>Riboflavin was also reported to ameliorate mitochondrial dysfunction and protect against oxidative stress [<xref rid="cit0022" ref-type="bibr">22</xref>]. This compound protected against hyperglycemia and DNA damage in diabetic mice [<xref rid="cit0037" ref-type="bibr">37</xref>]. As we mentioned, the action of riboflavin may depend on the genotype of the recipient. Therefore, it is not very surprising that in some mitochondrial diseases which are associated with mutations, the efficacy of this drug can be low. However, riboflavin-based therapy is considered as effective or possibly effective at various levels of recommendation by several institutions, including the American Academy of Neurology and the American Headache Society (<ext-link ext-link-type="uri" xlink:href="http://www.aan.com/guidelines">http://www.aan.com/guidelines</ext-link>).</p><p>Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a complex, progressive neurodegenerative disorder with a great variability in clinical picture causing difficulty with distinguishing it from vascular cerebral diseases, first of all cerebral infarctions [<xref rid="cit0038" ref-type="bibr">38</xref>]. Migraine shares some clinical characteristics with MELAS, including headaches with nausea and vomiting [<xref rid="cit0021" ref-type="bibr">21</xref>]. Another mitochondrial disease, myoclonic epilepsy with ragged-red fibers (MERRF), is also associated with episodes of hemicranial headaches. This provokes the question whether migraine can be a monosymptomatic form of MELAS or MERRF. However, no association of mutations typical for MELAS with migraine was reported. Klopstock <italic>et al</italic>. did not observe any association between MA and mutations (deletions and substitutions) common in MELAS and MERRF [<xref rid="cit0039" ref-type="bibr">39</xref>]. In a subsequent study, Buzzi <italic>et al.</italic> did not observe any association between the m.3243A&#x0003e;G substitution in the tRNA<sup>Leu</sup> gene and pure matrilineal multigenerational MA or MO [<xref rid="cit0040" ref-type="bibr">40</xref>]. In addition, neither patient enrolled in that study carried this mutation. No association of the m.3243A&#x0003e;G mutation with MO was observed [<xref rid="cit0041" ref-type="bibr">41</xref>]. In another study no association between nine point mutations (substitutions) and migraine with prolonged aura was observed [<xref rid="cit0042" ref-type="bibr">42</xref>]. Therefore, variability of mtDNA typical for MELAS is not reported to occur in migraine, and so these results do not support the thesis on migraine as a monosymptomatic form of MELAS. However, these studies, although carefully designed, were performed on relatively small populations. <xref rid="t0001" ref-type="table">Table I</xref> presents some diseases associated with migraine [<xref rid="cit0043" ref-type="bibr">43</xref>].</p><table-wrap id="t0001" position="float"><label>Table I</label><caption><p>Some clinical conditions associated with migraine [<xref rid="cit0043" ref-type="bibr">43</xref>]</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Condition</th><th align="center" rowspan="1" colspan="1">Disease</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="5" colspan="1">Genetic syndromes</td><td align="center" rowspan="1" colspan="1">Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)</td></tr><tr><td align="center" rowspan="1" colspan="1">Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</td></tr><tr><td align="center" rowspan="1" colspan="1">Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL)</td></tr><tr><td align="center" rowspan="1" colspan="1">Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS)</td></tr><tr><td align="center" rowspan="1" colspan="1">Fabry disease</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Vascular acquired diseases</td><td align="center" rowspan="1" colspan="1">Strokes: ischemic and hemorrhagic episodes</td></tr><tr><td align="center" rowspan="1" colspan="1">Transient ischemic attack (TIA) episodes</td></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">Mitochondrial diseases</td><td align="center" rowspan="1" colspan="1">Chronic progressive external ophthalmoplegia (CPEO)</td></tr><tr><td align="center" rowspan="1" colspan="1">Myoclonic epilepsy with ragged red fibers (MERRF)</td></tr><tr><td align="center" rowspan="1" colspan="1">Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS)</td></tr><tr><td align="center" rowspan="1" colspan="1">Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)</td></tr><tr><td align="center" rowspan="1" colspan="1">Myoclonic epilepsy with ragged-red fibers (MERRF)</td></tr><tr><td align="center" rowspan="1" colspan="1">Kearns-Sayre syndrome</td></tr><tr><td align="center" rowspan="1" colspan="1">Leber hereditary optic neuropathy</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Other diseases</td><td align="center" rowspan="1" colspan="1">Pediatric cyclic vomiting syndrome</td></tr><tr><td align="center" rowspan="1" colspan="1">Epilepsy</td></tr></tbody></table></table-wrap><p>Energy deficiency is especially important in muscles and neural tissue, particularly when combined with other stress, and contributes to many symptoms of mitochondrial myopathies [<xref rid="cit0044" ref-type="bibr">44</xref>]. Such myopathies associated with neurological disturbances are called mitochondrial encephalomyopathies. Several neurological symptoms occur also in migraine, including headaches, hearing impairment and seizures [<xref rid="cit0045" ref-type="bibr">45</xref>]. Therefore, some mitochondrial encephalomyopathies and migraine can share similar pathways of pathogenesis and so it is reasonable to look for a genetic background of migraine in mtDNA [<xref rid="cit0046" ref-type="bibr">46</xref>]. Moreover, this association allows one to speculate on the connection between migraine and epigenetic changes, which are reported for migraine comorbid disorders [<xref rid="cit0047" ref-type="bibr">47</xref>, <xref rid="cit0048" ref-type="bibr">48</xref>].</p></sec><sec id="sec4"><title>The human mitochondrial genome and its changes related to migraine</title><p>The human mitochondrial genome is a closed, double-stranded DNA (mtDNA) molecule of 16,569 bp, containing 37 genes encoding 2 rRNAs, 22 tRNAs and 13 polypeptides (<xref ref-type="fig" rid="f0004">Figure 4</xref>). All polypeptides encoded by mtDNA are subunits of ETS: 7 subunits of complex I (NADH: ubiquinone oxidoreductase), 1 subunit of complex III (ubiquinol:cytochrome c oxidoreductase), 3 subunits of complex IV (cytochrome c oxidase) and 2 subunits of complex V (ATP synthase). The entire complex III and all remaining subunits of complexes I, II, IV and V &#x02013; 79 subunits in total &#x02013; are encoded by nuclear DNA. Two strands of mtDNA are called heavy (H) and light (L) due to their base composition. mtDNA, in contrast to its nuclear counterpart, is densely packed with genetic information &#x02013; more than 90 percent of it contains coding sequences, genes are intron-less and the <italic>ATPase6</italic> and <italic>ATPase8</italic> genes overlap. A small non-coding mtDNA fragment is called the control region, as it contains almost all control elements of mtDNA metabolism. Due to the high variability of human mtDNA its variants are classified into haplotypes [<xref rid="cit0049" ref-type="bibr">49</xref>].</p><fig id="f0004" position="float"><label>Figure 4</label><caption><p>Human mitochondrium is a double membrane-bound organelle found in the cytoplasm. It usually contains several copies of mtDNA, which is a closed double-stranded DNA having heavy (H) and light (L) strands. It has 13 polypeptide encoding genes &#x02013; Cytb, ND1-6, ND4l, ATPase 6 and 8, COI-III &#x02013; whose products are components of the mitochondrial electron transport chain. Other genes of mtDNA are 2 rRNA and 22 tRNA genes. Promoters (P) for these genes (2 for heavy strand and 1 for light strand) are located in a single regulatory region, where also the origin for heavy strand replication occurs (O<sub>H</sub>)</p></caption><graphic xlink:href="AMS-15-36990-g004"/></fig><p>ETS is built from mitochondrial- and nuclear-encoded components and provides energy for the entire cell. However, even normally functioning ETS produces reactive oxygen species (ROS) and its malfunctioning increases ROS level. The importance and function of mitochondria should not be limited to energy production as this organelle plays an important role in calcium homeostasis and thermogenesis, the intrinsic pathway of apoptosis, signal transduction and other phenomena [<xref rid="cit0050" ref-type="bibr">50</xref>].</p><p>In humans, mtDNA does not recombine and is perpetuated exclusively in the maternal lineage. Therefore, it is useful for tracking genetic alterations through many generations. However, there are many mtDNA copies in a single cell, and not all of them need to be mutated to give a disease phenotype [<xref rid="cit0051" ref-type="bibr">51</xref>]. Therefore, mtDNA could also be exploited to track epigenetic changes sent from one generation to the next. However, epigenetic modifications to mtDNA have been far less exploited and are less well known than those to nuclear DNA.</p><p>mtDNA is characterized by greater sequence variation than its nuclear counterpart, but a cell usually has many mitochondria, which can have different genotypes. Therefore, wildtype mtDNA can occur along with its mutated variants in a single cell. This state is termed heteroplasmy in contrast to homoplasmy, which corresponds to the same sequence of a mtDNA locus in all mitochondria. Therefore, when a disease-associated variant occurs in a heteroplasmic form, its phenotypic consequences can be difficult to predict. In an extreme case, a lethal mutation in some mitochondria can be counterbalanced by the normal variant in remaining organelles. This creates a complex relationship between genetic variants in mtDNA and diseases. At a cellular level, a point mutation is considered to be expressed phenotypically with the threshold 80&#x02013;90%, but for a larger deletion the threshold is lower &#x02013; 50&#x02013;60% [<xref rid="cit0052" ref-type="bibr">52</xref>]. At the tissue level, the proportion of mutants can positively correlate with the severity of the disease [<xref rid="cit0053" ref-type="bibr">53</xref>].</p><p>As mentioned, a strong connection between migraine and mitochondria was evidenced by the observation that migraine-affected individuals have impaired brain energy metabolism [<xref rid="cit0054" ref-type="bibr">54</xref>]. Mitochondria play a vital role in energy production, apoptosis regulation and production of ROS even in normal conditions [<xref rid="cit0055" ref-type="bibr">55</xref>]. These ROS are important in cell signaling, but their excess can lead to damage to cellular molecules [<xref rid="cit0056" ref-type="bibr">56</xref>]. The main source of ROS is oxidative phosphorylation (OXPHOS), producing ATP from ADP and inorganic phosphate (P<sub>i</sub>), powered by the transfer of electrons from NADH/FADH<sub>2</sub> to O<sub>2</sub> [<xref rid="cit0057" ref-type="bibr">57</xref>]. This transfer is executed by mitochondrial ETS containing four large multiprotein complexes, designated I&#x02013;IV, located in the inner mitochondrial membrane, each having several electron carriers. The fifth complex, ATP synthase, accepts protons transported from the inner mitochondrial membrane, which fuel ATP productions. Additionally, inner membrane-bound ubiquinone and cytochrome <italic>c</italic>, located in the intermembrane space, play an important role in OXPHOS.</p><p>Oxidative stress is considered as a factor in migraine pathogenesis and is associated with an excess of ROS, which can damage DNA. However, Geyik <italic>et al</italic>. found no difference in oxidative stress markers, total oxidant status (TAS) and oxidative stress index (OSI) between migraine patients and controls [<xref rid="cit0058" ref-type="bibr">58</xref>]. An increased level of 8-hydroxy-2&#x02019;-deoxyguanosine (8-oxoG) in plasma of migraine patients was observed in that study and this increase was more pronounced in MO than MA patients. 8-oxoG is a product of oxidative DNA damage, which may lead to mutation if not repaired or misrepaired, and it is considered as an oxidative stress marker in humans. In similar studies, Alp <italic>et al.</italic> observed that serum TAS levels were lower in patients with MO as compared to controls and ROS levels in serum were higher in these patients [<xref rid="cit0059" ref-type="bibr">59</xref>]. Patients displayed higher values of OSI than controls, who, in turn, exhibited a higher levels of total SH groups, which were negatively correlated with headache duration. On the other hand, OSI was positively correlated with headache frequency. These studies have several limitations, including the small number of patients enrolled &#x02013; less than 100 migraine cases in either study. Moreover, the studies were performed in a non-target tissue and the parameters for assessing oxidative stress were chosen rather arbitrarily and they do not decide about the occurrence and intensity of oxidative stress. Furthermore, a higher level of 8-oxoG can result from impairment in the DNA repair system or in general an impaired DNA damage response. 8-oxoG is mainly removed by the base excision repair (BER) system and in humans the hOGG1 glycosylase cuts the <italic>N</italic>-glycosylic bond between 8-oxoG and the DNA sugar [<xref rid="cit0060" ref-type="bibr">60</xref>, <xref rid="cit0061" ref-type="bibr">61</xref>]. However, the results presented in those papers are a weak rationale to causatively correlate migraine with oxidative stress and allocate the source of this stress to mitochondria.</p><p>The brain is highly dependent on oxidative metabolism of glucose and therefore it is sensitive to changes in the functioning of mitochondria, which is supported by the association of several neurodegenerative diseases with mitochondrial dysfunction [<xref rid="cit0062" ref-type="bibr">62</xref>&#x02013;<xref rid="cit0064" ref-type="bibr">64</xref>].</p><p>Peroxisome proliferator-activated receptor-&#x003b3; coactivator-1&#x003b1; (PGC-1&#x003b1;) is an important regulator of the expression of genes involved in mitochondrial biogenesis and cellular reaction to oxidative stress [<xref rid="cit0065" ref-type="bibr">65</xref>, <xref rid="cit0066" ref-type="bibr">66</xref>]. Altered levels of mRNA of the <italic>PGC-1</italic>&#x003b1; gene along with a decreased number of mtDNA copies were observed in trigeminal neurons in a rat model of migraine [<xref rid="cit0067" ref-type="bibr">67</xref>].</p></sec><sec id="sec5"><title>Variability of mitochondrial DNA in migraine</title><p>The mitochondrial genome has limited autonomy as thousands of proteins which can be found in mitochondria are encoded in the nucleus. Therefore, the variability of nuclear genes involved in mitochondrial functioning may be important in migraine pathogenesis. The problem of genetic variability in migraine is connected with migraine hereditability. An identical twin study resulted in the conclusion of approximately 50% migraine hereditability [<xref rid="cit0068" ref-type="bibr">68</xref>].</p><p>A positive association between the m.4336A&#x0003e;G mutation, located on the <italic>tRNA<sup>Gln</sup></italic>, gene and sensorineural hearing loss and/or migraine was observed [<xref rid="cit0069" ref-type="bibr">69</xref>]. Wang <italic>et al.</italic> found an association between the occurrence of childhood cyclic vomiting, often considered as a migraine-like disease, and two rare heteroplasmic sequence variations containing 6 point and 2 length variants located in the mtDNA control region [<xref rid="cit0070" ref-type="bibr">70</xref>]. Two single nucleotide polymorphisms, m.16129G&#x0003e;A and m.16176C&#x0003e;T, in that region were associated with childhood cyclic vomiting. Moreover, these authors found that the homoplasmic variants located in the nt 16040-16188 segment of the highly variable region 1 (HV1) important in the regulation of mtDNA replication were associated with both cyclic vomiting syndrome and migraine without aura. In another study, Zaki <italic>et al.</italic> found an association between two mtDNA polymorphisms, m.16519C&#x0003e;T and m.3010G&#x0003e;A, and migraine headache and cyclic vomiting syndrome [<xref rid="cit0071" ref-type="bibr">71</xref>]. A higher, about three times, prevalence of migraine in individuals with the m.3243A&#x0003e;G mutation was reported [<xref rid="cit0072" ref-type="bibr">72</xref>]. This prevalence was observed in both MO and MA as well as in men and women separately. No association between the m.11084A&#x0003e;G polymorphism and migraine occurrence, whether MA or MO, in a Japanese population was found [<xref rid="cit0073" ref-type="bibr">73</xref>]. No difference between occurrence of the m.11084A&#x0003e;G mutation in MA and MO patients was observed in a Danish population [<xref rid="cit0074" ref-type="bibr">74</xref>]. This mutation was detected neither in migraine patients, MA or MO, nor controls. It has functional significance as it replaces adenine with guanine in the gene encoding the ND4 subunit of ETS complex I, resulting in the substitution of threonine with alanine. Interestingly, this mutation was reported to occur in a substantial fraction (about 25%) of Japanese migraineurs and was absent in tension-type headache patients and individuals with no migraine [<xref rid="cit0075" ref-type="bibr">75</xref>].</p><p>Mitochondrial haplogroup U, represented by the 12308A&#x0003e;G polymorphism, can play a role in migraine pathophysiology as this polymorphism was reported to associate with an increased risk of occipital stroke [<xref rid="cit0076" ref-type="bibr">76</xref>, <xref rid="cit0077" ref-type="bibr">77</xref>]. Also other haplogroups in mtDNA can be directly or indirectly related to migraine. Marcuello <italic>et al.</italic> reported an association between the J haplogroup and efficacy of energy production by ETS [<xref rid="cit0078" ref-type="bibr">78</xref>]. As mentioned, migraine is associated with energy deficit, so that haplogroup and its polymorphisms of mtDNA may influence the susceptibility to migraine as well as to other diseases associated with energy deficit.</p><p>Generally, there are few studies on the association between mtDNA variants and migraine occurrence and these studies are usually performed on relatively small populations. Therefore, they should be continued on larger cohorts. Moreover, studies on variants of nuclear genes encoding mitochondrial components and influencing mitochondrial function should be further developed, especially as they are free from several difficulties in mtDNA research, including heteroplasmy requiring sequencing of the entire mitochondrial genome with a high coverage. Therefore, further studies on the role of mtDNA disturbances in migraine are justified and needed.</p></sec><sec id="sec6"><title>Epigenetics of mtDNA and its potential in migraine</title><p>Epigenetics deals with mechanisms of the regulation of gene expression, which are not directly associated with changes in DNA sequences. Three major epigenetic mechanisms are related to DNA methylation, histone modifications and RNA regulation.</p><p>Two aspects of epigenetic regulation in migraine pathophysiology can be considered. One is related to transient changes in epigenetic profile, which may result in changes in phenotype. The other is associated with such changes in the epigenetic pattern, which are perpetuated from one generation to the next and contribute to familial cases of the disease.</p><p>Epigenetic therapy, i.e. therapy targeting the epigenetic profile of specific genes, is considered in many human disorders, first of all cancer, in which several epigenetic modifiers are tested in phase I and II clinical trials [<xref rid="cit0079" ref-type="bibr">79</xref>]. Such therapy is also considered in migraine [<xref rid="cit0080" ref-type="bibr">80</xref>]. Valproate, a histone deacetylate inhibitor, has been successfully tested in prophylaxis of several classes of migraine [<xref rid="cit0081" ref-type="bibr">81</xref>&#x02013;<xref rid="cit0085" ref-type="bibr">85</xref>]. However, its action cannot be unequivocally associated with an epigenetic mechanism as valproate is an anticonvulsive drug with several modes of action [<xref rid="cit0086" ref-type="bibr">86</xref>&#x02013;<xref rid="cit0088" ref-type="bibr">88</xref>]. Moreover, it is not known how valproate acts on mitochondria.</p><p>Passaro <italic>et al.</italic> found a direct correlation between epigenetic markers of the H3 histone associated with genes involved in neuronal plasticity and CSD in rat brain [<xref rid="cit0086" ref-type="bibr">86</xref>]. This study suggests a potentially important role of epigenetic modifications in migraine pathogenesis, which was supported by subsequent studies [<xref rid="cit0089" ref-type="bibr">89</xref>&#x02013;<xref rid="cit0091" ref-type="bibr">91</xref>]. Moreover, this importance has been recently confirmed by Gerring <italic>et al.</italic>, who have identified 62 independent regions in DNA isolated from peripheral blood of migraine patients, which were specifically methylated [<xref rid="cit0089" ref-type="bibr">89</xref>].</p><p>Many migraine comorbid mitochondrial diseases are associated with changes in the epigenetic profile [<xref rid="cit0046" ref-type="bibr">46</xref>]. Therefore, it is justified to explore the role of epigenetic modifications to mtDNA in migraine pathogenesis. However, the issue of epigenetics in mitochondria is still a matter of debate, with some controversial aspects [<xref rid="cit0092" ref-type="bibr">92</xref>]. As mtDNA is not associated with histones, its epigenetic modifications are limited in comparison with its nuclear counterpart, but mtDNA occurs in many copies and each of them could have a different epigenetic profile. Therefore, DNA methylation and regulatory RNAs are major players in epigenetic control of gene expression in mitochondria. In humans, DNA methylation of the CpG islands located in the promoters of many genes is of a particular significance. It is induced by DNA methyltransferases (DNMTs) 1/2 and 3A/B [<xref rid="cit0093" ref-type="bibr">93</xref>, <xref rid="cit0094" ref-type="bibr">94</xref>]. However, it should be stressed that mtDNA does not contain CpG islands, such as those targeted by DNA methyltransferases in the nucleus, but dispersed CpG dinucleotides occur in the mitochondrial genome [<xref rid="cit0095" ref-type="bibr">95</xref>]. Mitochondrial DNA methyltransferase 1 (mtDNMT1), an isoform of nuclear DNMT1, plays an important role in regulation of the expression of mitochondrial genes by modification of the mtDNA methylation profile [<xref rid="cit0088" ref-type="bibr">88</xref>]. This enzyme was reported to bind mtDNA in the region of the D-loop containing all three promoters needed for the transcription of mitochondrial genes, suggesting that mtDNMT1 can regulate gene expression. It was shown that DNMT1 interacted with CpG dinucleotides within mtDNA [<xref rid="cit0096" ref-type="bibr">96</xref>]. There is another DNA methyltransferase in the nucleus, DNMT3L, which, on binding with unmethylated lysines in H3 histone, guides DNMT3A/3B to DNA [<xref rid="cit0097" ref-type="bibr">97</xref>]. As there is no H3 histone in mitochondria, the potential of this enzyme seems to be lower than remaining DNA methyltransferases. However, DNMT3L is involved in DNA methylation in the nucleus, so it can play a role in the expression of genes whose products are important for mitochondrial homeostasis.</p><p>Another DNA methyltransferase, DNMT3A, was localized in the mitochondria of neurons and its decreased activity was reported to be associated with an abnormal mtDNA methylation pattern in amyotrophic lateral sclerosis, a progressive neurological disease [<xref rid="cit0098" ref-type="bibr">98</xref>]. However, it should be taken into account that in contrast to mtDNMT1, DNMT3A was not specifically targeted to mitochondria, but was found in these organelles. The identification of DNA methyltransferases operating in mitochondria shed light on the epigenetic mechanisms in these organelles, but on the other hand, it has added to the complexity of this issue [<xref rid="cit0099" ref-type="bibr">99</xref>]. Other epigenetics-related proteins detected in mitochondria are DNMT3B and two proteins involved in active demethylation, ten-eleven translocation (TET) 1 and 2 [<xref rid="cit0100" ref-type="bibr">100</xref>&#x02013;<xref rid="cit0103" ref-type="bibr">103</xref>]. These methyltransferases are not only encoded in the nucleus, but are isoforms of nuclear proteins. Therefore, precise regulation of their expression and functions is required for cellular homeostasis and disease-related changes in their activity can result from an imbalanced nuclear-mitochondrial cross-talk [<xref rid="cit0104" ref-type="bibr">104</xref>]. However, some reports question the process of mtDNA cytosine methylation, indicating limitations of techniques employed in earlier studies [<xref rid="cit0105" ref-type="bibr">105</xref>].</p><p>The third aspect of epigenetics, RNA regulation, is first of all based on three kinds of non-coding (nc) regulatory RNAs: short ncRNA, including micro RNA (miRNA) of 22&#x02013;23 bases in length (b) and piwi-interacting RNA (piRNA) of 26&#x02013;31 b; medium ncRNA of 50&#x02013;200 b and long non-coding RNA (lncRNA) longer than 200 b [<xref rid="cit0106" ref-type="bibr">106</xref>].</p><p>Micro RNA regulation is important in the nervous system [<xref rid="cit0107" ref-type="bibr">107</xref>, <xref rid="cit0108" ref-type="bibr">108</xref>]. RNA interference components, including miRNAs and Argonaute proteins, were localized to mitochondria, showing another aspect of the cross-talk between the nucleus and mitochondria through an array of miRNAs, which are called &#x0201c;mitomiRs&#x0201d; [<xref rid="cit0108" ref-type="bibr">108</xref>].</p><p>Long non-coding RNAs are another element of epigenetic regulation, and in the nuclear genome it is associated with several important aspects of the regulation of gene expression, including chromosome X inactivation [<xref rid="cit0109" ref-type="bibr">109</xref>]. lncRNA regulation is important in many cancers, including brain tumors [<xref rid="cit0110" ref-type="bibr">110</xref>, <xref rid="cit0111" ref-type="bibr">111</xref>].</p><p>The mitochondrial transcriptome is quite complex and should not be limited to 37 mtDNA genes, as almost the whole mitochondrial genome is transcribed &#x02013; 99.9% of H and 97.6% of the L strand were reported to undergo transcription [<xref rid="cit0112" ref-type="bibr">112</xref>]. Many antisense transcripts can be found within the mitochondrial transcriptome. Moreover, many RNAs encoded in the nucleus are present in mitochondria and <italic>vice versa</italic> &#x02013; several mitochondria-borne RNAs were reported to operate in the nucleus, indicating the importance of the mitochondria-nucleus cross-talk [<xref rid="cit0113" ref-type="bibr">113</xref>]. Altogether, many both &#x0201c;short&#x0201d; and &#x0201c;long&#x0201d; regulatory RNAs, including miRNAs and lncRNAs, can be found in mitochondria, and they can play an important role in the regulation of gene expression. In general, two species, miRNA and lncRNA, seem to be mutually regulated within the miRNA-lncRNA axis giving the functional balance between lncRNAs and miRNAs &#x02013; the lncRNA-miRNA paradigm [<xref rid="cit0114" ref-type="bibr">114</xref>]. Departures from this paradigm can contribute to disturbances in energy production and can affect other processes in mitochondria important for the cell fate, which may result in disorders [<xref rid="cit0115" ref-type="bibr">115</xref>]. However, to our knowledge the role of lncRNA, either nuclear or mitochondrial, in migraine pathophysiology has not been explored so far. An association between disturbances in lncRNA functioning and mitochondrial impairment was observed in Down syndrome [<xref rid="cit0116" ref-type="bibr">116</xref>].</p><p>The mitochondria-nucleus cross-talk can also be expressed by the changes in the nuclear epigenetic profile reflected in mitochondria functioning, which in turn results in the global changes to the whole organism, as in the case of mitochondrial lifespan extension dependent on stress [<xref rid="cit0117" ref-type="bibr">117</xref>].</p><p>Several loci associated with migraine in the human genome have been identified in genome-wide association studies (GWAS) [<xref rid="cit0118" ref-type="bibr">118</xref>, <xref rid="cit0119" ref-type="bibr">119</xref>]. Some of them can be linked with epigenetic mechanisms [<xref rid="cit0120" ref-type="bibr">120</xref>]. However, it should be underlined that no genes directly involved in establishing and maintaining the epigenetic profile, such as DNA methyltransferases or histone deacetylases, have been found in these studies. Moreover, GWAS studies did not provide results on the link between mtDNA variability and migraine.</p></sec><sec id="sec7"><title>Conclusions and perspectives</title><p>Epigenetic mechanisms are an important element of the control of gene expression. Transcriptional regulation through RNA molecules is essential for many genes [<xref rid="cit0121" ref-type="bibr">121</xref>, <xref rid="cit0122" ref-type="bibr">122</xref>]. On the other hand, the epigenetic profile undergoes changes induced by environmental conditions. Oxidative stress is linked with pathophysiology of many diseases, including migraine. However, in most cases it is not completely known whether the stress belongs to the reasons or consequences of a disease, or both. It is difficult to find a disorder not linked to oxidative stress in its pathogenesis. On the other hand, ROS are normally produced in mitochondria. Therefore, many oxidative stress-related disorders can be potentially linked with mitochondria. Consequently, association of a mitochondrial dysfunction with a clinically detectable disorder may result from a false positive correlation. Oxidative stress, resulting from impaired functioning of ETS, may lead to the accumulation of damage to cellular components and mitochondrial aging, cellular senescence and premature organismal aging. So far, no mtDNA damage in migraine has been reported, but the extent of mtDNA damage in the brain of mammals was negatively correlated with maximal life span [<xref rid="cit0022" ref-type="bibr">22</xref>].</p><p>Abnormal expression of PGC-1&#x003b1; in neurons of a rat model of migraine provokes a question about the potential role of this protein in the pathogenesis of human migraine. Moreover, the involvement of PGC-1&#x003b1; in mitochondrial biogenesis prompts the search for the role of mitophagy, a key element in the regulation of mitochondrial number, in migraine pathogenesis [<xref rid="cit0123" ref-type="bibr">123</xref>].</p><p>Migraine can be diagnosed as an isolated headache with autonomic symptoms or as a part of a syndrome associated with other complex diseases, including mitochondrial disorders. There is no general agreement whether these two categories of migraine are different or not. Some reports suggest that there are essential differences between these two forms of migraine not resulting from individual susceptibility to this disease. These differences are claimed to manifest first of all with a prolonged aura and stroke-like episodes in migraine associated with other diseases. However, Vollono <italic>et al</italic>. recently observed migraine without aura in about 80% of mitochondrial disease cases [<xref rid="cit0043" ref-type="bibr">43</xref>]. Therefore, it may be difficult to distinguish autonomous migraine from migraine associated with other diseases.</p><p>Several mitochondrial encephalomyopathies share neurological symptoms with migraine, which may follow from a common mitochondrial element in their pathogeneses. As no migraine-specific mutations in mtDNA have been identified yet, it is likely that this common element can be of epigenetic nature. The brain needs energy in the form of ATP, produced mainly in mitochondria, and disturbance in its supply can result in an increased sensitivity to migraine attack.</p><p>Complex mitochondrial diseases cannot be related exclusively to mtDNA as they are associated with mitochondrial proteins encoded by nuclear genes. Therefore, a complex genomic analysis including both mitochondrial and nuclear components of the human genome should be performed in research on pathogenesis of these diseases. Mitochondrial variation need to be studied in large family pedigree studies to find a correlation between mtDNA mutation and migraine to eventually identify true causal variants. Moreover, these studies should also include variability in relevant nuclear genes. Currently, the MitoProteome Human Mitochondrial Protein Database lists 3,625 proteins, including isoforms and splice variants, which can be allocated to mitochondria (<ext-link ext-link-type="uri" xlink:href="http://mitoproteome.org/">http://mitoproteome.org/</ext-link>).</p><p>Riboflavin proved to be effective in migraine prophylaxis in several clinical trials. However, some issues concerning the methodology of these trials as well as basic questions on riboflavin pharmacokinetics and pharmacogenomics should be addressed. These concern first of all interpretation of results of trials with n placebo groups and determination of optimal doses of riboflavin as the mechanism of its absorption is not completely known.</p><p>In clinical practice, it is important to distinguish migraine from monosymptomatic forms of other diseases manifested by headaches, first of all MELAS, especially considering that migraine can share morbidity with some mitochondrial disorders.</p><p>Mitochondria add complexity to migraine pathogenesis. Therefore, new integrated approaches are needed to better understand migraine pathophysiology and translate molecular research into clinical practice to improve diagnosis and therapy of this disease.</p><p>The question from the title of this paper remains open. First of all, we must extend and deepen our knowledge on epigenetic regulation in mitochondria. mtDNA has a specific structure, which can constitute a barrier in the determination of mtDNA epigenetic pattern with methods established for its nuclear counterpart, as was shown for cytosine methylation in the D-loop. Therefore, the initial enthusiasm associated with mtDNA methylation should be revised [<xref rid="cit0118" ref-type="bibr">118</xref>]. This is especially important as the functional relevance of mtDNA methylation has been supported only by association studies and no reliable mechanistic research on this subject has been performed. Secondly, although accumulating body of evidence suggests the involvement of mitochondria in migraine pathogenesis, the exact mechanism of this involvement is unknown. The potential role of mitochondrially enriched miRNAs (mitomiRNAs) in migraine pathogenesis should be investigated.</p><p>GWAS provided information on many loci which can be linked to migraine, so epigenome-wide association studies with several high-throughput analyses may bring more information on the role of epigenetics in migraine. However, the evaluation of the significance of mitochondrial genome/epigenome in migraine pathophysiology requires new methods and approaches.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooch</surname><given-names>CL</given-names></name><name><surname>Pracht</surname><given-names>E</given-names></name><name><surname>Borenstein</surname><given-names>AR</given-names></name></person-group><article-title>The burden of neurological disease in the United States: a summary report and call to action</article-title><source>Ann Neurol</source><year>2017</year><volume>81</volume><fpage>479</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">28198092</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>A</given-names></name></person-group><article-title>The pathophysiology of migraine: implications for clinical management</article-title><source>Lancet Neurol</source><year>2017</year><volume>17</volume><fpage>174</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">29229375</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MB</given-names></name><name><surname>Hadjikhani</surname><given-names>N</given-names></name></person-group><article-title>Migraine aura and related phenomena: beyond scotomata and scintillations</article-title><source>Cephalalgia</source><year>2007</year><volume>27</volume><fpage>1368</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">17944958</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warfvinge</surname><given-names>K</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Pearls and pitfalls in neural CGRP immunohistochemistry</article-title><source>Cephalalgia</source><year>2013</year><volume>33</volume><fpage>593</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">23671255</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TW</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>CGRP and its receptors provide new insights into migraine pathophysiology</article-title><source>Nature Rev Neurol</source><year>2010</year><volume>6</volume><fpage>573</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">20820195</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Welch</surname><given-names>KM</given-names></name><name><surname>Al-Sayed</surname><given-names>F</given-names></name></person-group><article-title>The threshold for phosphenes is lower in migraine</article-title><source>Cephalalgia</source><year>2003</year><volume>23</volume><fpage>258</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12716342</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulleners</surname><given-names>WM</given-names></name><name><surname>Chronicle</surname><given-names>EP</given-names></name><name><surname>Palmer</surname><given-names>JE</given-names></name><name><surname>Koehler</surname><given-names>PJ</given-names></name><name><surname>Vredeveld</surname><given-names>JW</given-names></name></person-group><article-title>Visual cortex excitability in migraine with and without aura</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>565</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">11437892</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyngoudt</surname><given-names>H</given-names></name><name><surname>Paemeleire</surname><given-names>K</given-names></name><name><surname>Descamps</surname><given-names>B</given-names></name><name><surname>De Deene</surname><given-names>Y</given-names></name><name><surname>Achten</surname><given-names>E</given-names></name></person-group><article-title>31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>1243</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21289000</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>W</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name><name><surname>Bloom</surname><given-names>M</given-names></name><name><surname>Gebeline-Myers</surname><given-names>C</given-names></name></person-group><article-title>Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects</article-title><source>Headache</source><year>2008</year><volume>48</volume><fpage>1490</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19076647</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SP</given-names></name><name><surname>Ayata</surname><given-names>C</given-names></name></person-group><article-title>Spreading depression in primary and secondary headache disorders</article-title><source>Curr Pain Headache Rep</source><year>2016</year><volume>20</volume><fpage>44</fpage><pub-id pub-id-type="pmid">27215627</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagna</surname><given-names>P</given-names></name></person-group><article-title>Magnetic resonance spectroscopy in migraine</article-title><source>Cephalalgia</source><year>1995</year><volume>15</volume><fpage>323</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7585931</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Silvestro</surname><given-names>M</given-names></name><name><surname>Tedeschi</surname><given-names>G</given-names></name><name><surname>Tessitore</surname><given-names>A</given-names></name></person-group><article-title>Physiopathology of migraine: what have we learned from functional imaging?</article-title><source>Curr Neurol Neurosci Rep</source><year>2017</year><volume>17</volume><fpage>95</fpage><pub-id pub-id-type="pmid">29063211</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Tarducci</surname><given-names>R</given-names></name><name><surname>Presciutti</surname><given-names>O</given-names></name><etal/></person-group><article-title>Functional 1H-MRS findings in migraine patients with and without aura assessed interictally</article-title><source>Neuroimage</source><year>2005</year><volume>24</volume><fpage>1025</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15670679</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparaco</surname><given-names>M</given-names></name><name><surname>Feleppa</surname><given-names>M</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Rapoport</surname><given-names>AM</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name></person-group><article-title>Mitochondrial dysfunction and migraine: evidence and hypotheses</article-title><source>Cephalalgia</source><year>2006</year><volume>26</volume><fpage>361</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16556237</pub-id></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>C</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Sirianni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Migraine improvement during short lasting ketogenesis: a proof-of-concept study</article-title><source>Eur J Neurol</source><year>2015</year><volume>22</volume><fpage>170</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25156013</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>EG</given-names></name><name><surname>Chaffe</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>RH</given-names></name><etal/></person-group><article-title>A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy</article-title><source>Epilepsia</source><year>2009</year><volume>50</volume><fpage>1109</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">19054400</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Onofrio</surname><given-names>F</given-names></name><name><surname>Raimo</surname><given-names>S</given-names></name><name><surname>Spitaleri</surname><given-names>D</given-names></name><name><surname>Casucci</surname><given-names>G</given-names></name><name><surname>Bussone</surname><given-names>G</given-names></name></person-group><article-title>Usefulness of nutraceuticals in migraine prophylaxis</article-title><source>Neurol Sci</source><year>2017</year><volume>38</volume><fpage>S117</fpage><lpage>120</lpage></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaul</surname><given-names>C</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Danesch</surname><given-names>U</given-names></name></person-group><article-title>Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial</article-title><source>J Headache Pain</source><year>2015</year><volume>16</volume><fpage>516</fpage><pub-id pub-id-type="pmid">25916335</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>SK</given-names></name><name><surname>Nelson</surname><given-names>TD</given-names></name><name><surname>Kabbouche</surname><given-names>MA</given-names></name><etal/></person-group><article-title>A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>897</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">21586650</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraya</surname><given-names>T</given-names></name><name><surname>Deschauer</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>PR</given-names></name><name><surname>Zierz</surname><given-names>S</given-names></name><name><surname>Gaul</surname><given-names>C</given-names></name></person-group><article-title>Prevalence of headache in patients with mitochondrial disease: a cross-sectional study</article-title><source>Headache</source><year>2018</year><volume>58</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">29139113</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollono</surname><given-names>C</given-names></name><name><surname>Primiano</surname><given-names>G</given-names></name><name><surname>Della Marca</surname><given-names>G</given-names></name><name><surname>Losurdo</surname><given-names>A</given-names></name><name><surname>Servidei</surname><given-names>S</given-names></name></person-group><article-title>Migraine in mitochondrial disorders: prevalence and characteristics</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>1093</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">28762753</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barja</surname><given-names>G</given-names></name><name><surname>Herrero</surname><given-names>A</given-names></name></person-group><article-title>Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals</article-title><source>FASEB J</source><year>2000</year><volume>14</volume><fpage>312</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10657987</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>DO</given-names></name></person-group><article-title>B Vitamins and the braIn: mechanisms, dose and efficacy &#x02013; a review</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><fpage>68</fpage><pub-id pub-id-type="pmid">26828517</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernsen</surname><given-names>PL</given-names></name><name><surname>Gabreels</surname><given-names>FJ</given-names></name><name><surname>Ruitenbeek</surname><given-names>W</given-names></name><name><surname>Hamburger</surname><given-names>HL</given-names></name></person-group><article-title>Treatment of complex I deficiency with riboflavin</article-title><source>J Neurol Sci</source><year>1993</year><volume>118</volume><fpage>181</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8229067</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darin</surname><given-names>N</given-names></name><name><surname>Hedberg-Oldfors</surname><given-names>C</given-names></name><name><surname>Kroksmark</surname><given-names>AK</given-names></name><name><surname>Moslemi</surname><given-names>AR</given-names></name><name><surname>Kollberg</surname><given-names>G</given-names></name><name><surname>Oldfors</surname><given-names>A</given-names></name></person-group><article-title>Benign mitochondrial myopathy with exercise intolerance in a large multigeneration family due to a homoplasmic m.3250T&#x0003e;C mutation in MTTL1</article-title><source>Eur J Neurol</source><year>2017</year><volume>24</volume><fpage>587</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">28181352</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henriques</surname><given-names>BJ</given-names></name><name><surname>Lucas</surname><given-names>TG</given-names></name><name><surname>Gomes</surname><given-names>CM</given-names></name></person-group><article-title>Therapeutic approaches using riboflavin in mitochondrial energy metabolism disorders</article-title><source>Curr Drug Targets</source><year>2016</year><volume>17</volume><fpage>1527</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">27527619</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Wang</surname><given-names>DN</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name></person-group><article-title>A historical cohort study on the efficacy of glucocorticoids and riboflavin among patients with late-onset multiple acyl-CoA dehydrogenase deficiency</article-title><source>Chin Med J (Engl)</source><year>2016</year><volume>129</volume><fpage>142</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26830983</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>RKJ</given-names></name><name><surname>Konarikova</surname><given-names>E</given-names></name><name><surname>Giancaspero</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Riboflavin-responsive and -non-responsive mutations in FAD synthase cause multiple Acyl-CoA dehydrogenase and combined respiratory chain deficiency</article-title><source>Am J Hum Genet</source><year>2016</year><volume>98</volume><fpage>1130</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">27259049</pub-id></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>K</given-names></name><name><surname>Tomar</surname><given-names>SK</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Mandal</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name></person-group><article-title>Riboflavin and health: a review of recent human research</article-title><source>Crit Rev Food Sci Nutr</source><year>2017</year><volume>57</volume><fpage>3650</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">27029320</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>DF</given-names></name><name><surname>Saluja</surname><given-names>HS</given-names></name></person-group><article-title>Prophylaxis of migraine headaches with riboflavIn: a systematic review</article-title><source>J Clin Pharm Ther</source><year>2017</year><volume>42</volume><fpage>394</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">28485121</pub-id></element-citation></ref><ref id="cit0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>O</given-names></name><name><surname>Mauskop</surname><given-names>A</given-names></name></person-group><article-title>Nutraceuticals in acute and prophylactic treatment of migraine</article-title><source>Curr Treat Options Neurol</source><year>2016</year><volume>18</volume><fpage>14</fpage><pub-id pub-id-type="pmid">26923604</pub-id></element-citation></ref><ref id="cit0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marashly</surname><given-names>ET</given-names></name><name><surname>Bohlega</surname><given-names>SA</given-names></name></person-group><article-title>Riboflavin has neuroprotective potential: focus on parkinson&#x02019;s disease and migraine</article-title><source>Front Neurol</source><year>2017</year><volume>8</volume><fpage>333</fpage><pub-id pub-id-type="pmid">28775706</pub-id></element-citation></ref><ref id="cit0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namazi</surname><given-names>N</given-names></name><name><surname>Heshmati</surname><given-names>J</given-names></name><name><surname>Tarighat-Esfanjani</surname><given-names>A</given-names></name></person-group><article-title>Supplementation with riboflavin (Vitamin B2) for migraine prophylaxis in adults and children: a review</article-title><source>Int J Vitam Nutr Res</source><year>2015</year><volume>85</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">26780280</pub-id></element-citation></ref><ref id="cit0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>C</given-names></name><name><surname>Pierelli</surname><given-names>F</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><etal/></person-group><article-title>Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs</article-title><source>Neurology</source><year>2009</year><volume>72</volume><fpage>1588</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">19414726</pub-id></element-citation></ref><ref id="cit0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoenen</surname><given-names>J</given-names></name><name><surname>Jacquy</surname><given-names>J</given-names></name><name><surname>Lenaerts</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of high-dose riboflavin in migraine prophylaxis</article-title><source>A randomized controlled trial. Neurology</source><year>1998</year><volume>50</volume><fpage>466</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9484373</pub-id></element-citation></ref><ref id="cit0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimdel</surname><given-names>A</given-names></name><name><surname>Zeinali</surname><given-names>A</given-names></name><name><surname>Yazdian-Anari</surname><given-names>P</given-names></name><name><surname>Hajizadeh</surname><given-names>R</given-names></name><name><surname>Arefnia</surname><given-names>E</given-names></name></person-group><article-title>Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial</article-title><source>Electron Physician</source><year>2015</year><volume>7</volume><fpage>1344</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26516440</pub-id></element-citation></ref><ref id="cit0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alam</surname><given-names>MM</given-names></name><name><surname>Iqbal</surname><given-names>S</given-names></name><name><surname>Naseem</surname><given-names>I</given-names></name></person-group><article-title>Ameliorative effect of riboflavin on hyperglycemia, oxidative stress and DNA damage in type-2 diabetic mice: mechanistic and therapeutic strategies</article-title><source>Arch Biochem Biophys</source><year>2015</year><volume>584</volume><fpage>10</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26319175</pub-id></element-citation></ref><ref id="cit0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>K</given-names></name><name><surname>Liebeskind</surname><given-names>DS</given-names></name></person-group><article-title>Imaging of MELAS</article-title><source>Curr Pain Headache Rep</source><year>2016</year><volume>20</volume><fpage>54</fpage><pub-id pub-id-type="pmid">27477183</pub-id></element-citation></ref><ref id="cit0039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klopstock</surname><given-names>T</given-names></name><name><surname>May</surname><given-names>A</given-names></name><name><surname>Seibel</surname><given-names>P</given-names></name><name><surname>Papagiannuli</surname><given-names>E</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Reichmann</surname><given-names>H</given-names></name></person-group><article-title>Mitochondrial DNA in migraine with aura</article-title><source>Neurology</source><year>1996</year><volume>46</volume><fpage>1735</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8649580</pub-id></element-citation></ref><ref id="cit0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzzi</surname><given-names>MG</given-names></name><name><surname>Di Gennaro</surname><given-names>G</given-names></name><name><surname>D&#x02019;Onofrio</surname><given-names>M</given-names></name><etal/></person-group><article-title>mtDNA A3243G MELAS mutation is not associated with multigenerational female migraine</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>1005</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10691007</pub-id></element-citation></ref><ref id="cit0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Gennaro</surname><given-names>G</given-names></name><name><surname>Buzzi</surname><given-names>MG</given-names></name><name><surname>Ciccarelli</surname><given-names>O</given-names></name><etal/></person-group><article-title>Assessing the relative incidence of mitochondrial DNA A3243G in migraine without aura with maternal inheritance</article-title><source>Headache</source><year>2000</year><volume>40</volume><fpage>568</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10940095</pub-id></element-citation></ref><ref id="cit0042"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozen</surname><given-names>TD</given-names></name><name><surname>Shanske</surname><given-names>S</given-names></name><name><surname>Otaegui</surname><given-names>D</given-names></name><etal/></person-group><article-title>Study of mitochondrial DNA mutations in patients with migraine with prolonged aura</article-title><source>Headache</source><year>2004</year><volume>44</volume><fpage>674</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15209689</pub-id></element-citation></ref><ref id="cit0043"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollono</surname><given-names>C</given-names></name><name><surname>Primiano</surname><given-names>G</given-names></name><name><surname>Della Marca</surname><given-names>G</given-names></name><name><surname>Losurdo</surname><given-names>A</given-names></name><name><surname>Servidei</surname><given-names>S</given-names></name></person-group><article-title>Migraine in mitochondrial disorders: prevalence and characteristics</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>1093</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">28762753</pub-id></element-citation></ref><ref id="cit0044"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiMauro</surname><given-names>S</given-names></name><name><surname>Bonilla</surname><given-names>E</given-names></name><name><surname>Zeviani</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>DeVivo</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondrial myopathies</article-title><source>Ann Neurol</source><year>1985</year><volume>17</volume><fpage>521</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">3927817</pub-id></element-citation></ref><ref id="cit0045"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomyn</surname><given-names>A</given-names></name><name><surname>Enriquez</surname><given-names>JA</given-names></name><name><surname>Micol</surname><given-names>V</given-names></name><name><surname>Fernandez-Silva</surname><given-names>P</given-names></name><name><surname>Attardi</surname><given-names>G</given-names></name></person-group><article-title>The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>19198</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">10858457</pub-id></element-citation></ref><ref id="cit0046"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos-Araujo</surname><given-names>D</given-names></name><name><surname>Stuart</surname><given-names>S</given-names></name><name><surname>Lea</surname><given-names>RA</given-names></name><name><surname>Haupt</surname><given-names>LM</given-names></name><name><surname>Griffiths</surname><given-names>LR</given-names></name></person-group><article-title>Epigenetics and migraine; complex mitochondrial interactions contributing to disease susceptibility</article-title><source>Gene</source><year>2014</year><volume>543</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24704026</pub-id></element-citation></ref><ref id="cit0047"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>IA</given-names></name><name><surname>Mehler</surname><given-names>MF</given-names></name></person-group><article-title>Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis</article-title><source>Neurobiol Dis</source><year>2010</year><volume>39</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">20188170</pub-id></element-citation></ref><ref id="cit0048"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Kennedy</surname><given-names>PJ</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><article-title>Epigenetics of the depressed braIn: role of histone acetylation and methylation</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><fpage>124</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">22692567</pub-id></element-citation></ref><ref id="cit0049"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan-Richards</surname><given-names>M</given-names></name><name><surname>Bulgarella</surname><given-names>M</given-names></name><name><surname>Sivyer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Explaining large mitochondrial sequence differences within a population sample</article-title><source>R Soc Open Sci</source><year>2017</year><volume>4</volume><fpage>170730</fpage><pub-id pub-id-type="pmid">29291063</pub-id></element-citation></ref><ref id="cit0050"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>S</given-names></name><name><surname>Martino</surname><given-names>PL</given-names></name><name><surname>Capitanio</surname><given-names>G</given-names></name><etal/></person-group><article-title>The oxidative phosphorylation system in mammalian mitochondria</article-title><source>Adv Exp Med Biol</source><year>2012</year><volume>942</volume><fpage>3</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">22399416</pub-id></element-citation></ref><ref id="cit0051"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>CT</given-names></name><name><surname>Schon</surname><given-names>EA</given-names></name><name><surname>DiMauro</surname><given-names>S</given-names></name><name><surname>Miranda</surname><given-names>AF</given-names></name></person-group><article-title>Heteroplasmy of mitochondrial genomes in clonal cultures from patients with Kearns-Sayre syndrome</article-title><source>Biochem Biophys Res Commun</source><year>1989</year><volume>160</volume><fpage>765</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">2541710</pub-id></element-citation></ref><ref id="cit0052"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>R</given-names></name><name><surname>Faustin</surname><given-names>B</given-names></name><name><surname>Rocher</surname><given-names>C</given-names></name><name><surname>Malgat</surname><given-names>M</given-names></name><name><surname>Mazat</surname><given-names>JP</given-names></name><name><surname>Letellier</surname><given-names>T</given-names></name></person-group><article-title>Mitochondrial threshold effects</article-title><source>Biochem J</source><year>2003</year><volume>370</volume><fpage>751</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12467494</pub-id></element-citation></ref><ref id="cit0053"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinnery</surname><given-names>PF</given-names></name><name><surname>Hudson</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial genetics</article-title><source>Br Med Bull</source><year>2013</year><volume>106</volume><fpage>135</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">23704099</pub-id></element-citation></ref><ref id="cit0054"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uncini</surname><given-names>A</given-names></name><name><surname>Lodi</surname><given-names>R</given-names></name><name><surname>Di Muzio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Abnormal brain and muscle energy metabolism shown by 31P-MRS in familial hemiplegic migraine</article-title><source>J Neurol Sci</source><year>1995</year><volume>129</volume><fpage>214</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">7608738</pub-id></element-citation></ref><ref id="cit0055"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaban</surname><given-names>Y</given-names></name><name><surname>Boekema</surname><given-names>EJ</given-names></name><name><surname>Dudkina</surname><given-names>NV</given-names></name></person-group><article-title>Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation</article-title><source>Biochim Biophys Acta</source><year>2014</year><volume>1837</volume><fpage>418</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">24183696</pub-id></element-citation></ref><ref id="cit0056"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shadel</surname><given-names>GS</given-names></name><name><surname>Horvath</surname><given-names>TL</given-names></name></person-group><article-title>Mitochondrial ROS signaling in organismal homeostasis</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>560</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26496603</pub-id></element-citation></ref><ref id="cit0057"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>L</given-names></name><name><surname>Laporte</surname><given-names>D</given-names></name><name><surname>Duvezin-Caubet</surname><given-names>S</given-names></name><name><surname>Courtout</surname><given-names>F</given-names></name><name><surname>Sagot</surname><given-names>I</given-names></name></person-group><article-title>Mitochondrial ATP synthases cluster as discrete domains that reorganize with the cellular demand for oxidative phosphorylation</article-title><source>J Cell Sci</source><year>2014</year><volume>127</volume><fpage>719</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">24338369</pub-id></element-citation></ref><ref id="cit0058"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyik</surname><given-names>S</given-names></name><name><surname>Altunisik</surname><given-names>E</given-names></name><name><surname>Neyal</surname><given-names>AM</given-names></name><name><surname>Taysi</surname><given-names>S</given-names></name></person-group><article-title>Oxidative stress and DNA damage in patients with migraine</article-title><source>J Headache Pain</source><year>2016</year><volume>17</volume><fpage>10</fpage><pub-id pub-id-type="pmid">26883365</pub-id></element-citation></ref><ref id="cit0059"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alp</surname><given-names>R</given-names></name><name><surname>Selek</surname><given-names>S</given-names></name><name><surname>Alp</surname><given-names>SI</given-names></name><name><surname>Taskin</surname><given-names>A</given-names></name><name><surname>Kocyigit</surname><given-names>A</given-names></name></person-group><article-title>Oxidative and antioxidative balance in patients of migraine</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2010</year><volume>14</volume><fpage>877</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">21222375</pub-id></element-citation></ref><ref id="cit0060"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>NC</given-names></name><name><surname>Corbett</surname><given-names>AH</given-names></name><name><surname>Doetsch</surname><given-names>PW</given-names></name></person-group><article-title>The current state of eukaryotic DNA base damage and repair</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>10083</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">26519467</pub-id></element-citation></ref><ref id="cit0061"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>T</given-names></name></person-group><article-title>The intrinsic fragility of DNA (Nobel Lecture)</article-title><source>Angew Chem Int Ed Engl</source><year>2016</year><volume>55</volume><fpage>8528</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">27220039</pub-id></element-citation></ref><ref id="cit0062"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anamika</surname></name><name><surname>Khanna</surname><given-names>A</given-names></name><name><surname>Acharjee</surname><given-names>P</given-names></name><name><surname>Acharjee</surname><given-names>A</given-names></name><name><surname>Trigun</surname><given-names>SK</given-names></name></person-group><article-title>Mitochondrial SIRT3 and neurodegenerative brain disorders</article-title><source>J Chem Neuroanat</source><year>2019</year><volume>95</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">29129747</pub-id></element-citation></ref><ref id="cit0063"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamata</surname><given-names>H</given-names></name><name><surname>Manfredi</surname><given-names>G</given-names></name></person-group><article-title>Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases</article-title><source>J Cell Biol</source><year>2017</year><volume>216</volume><fpage>3917</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">29167179</pub-id></element-citation></ref><ref id="cit0064"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Magrane</surname><given-names>J</given-names></name><name><surname>Rattelle</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early cerebellar deficits in mitochondrial biogenesis and respiratory chain complexes in the KIKO mouse model of Friedreich ataxia</article-title><source>Dis Model Mech</source><year>2017</year><volume>10</volume><fpage>1343</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">29125827</pub-id></element-citation></ref><ref id="cit0065"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldelli</surname><given-names>S</given-names></name><name><surname>Aquilano</surname><given-names>K</given-names></name><name><surname>Ciriolo</surname><given-names>MR</given-names></name></person-group><article-title>PGC-1&#x003b1; buffers ROS-mediated removal of mitochondria during myogenesis</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><fpage>e1515</fpage><pub-id pub-id-type="pmid">25375380</pub-id></element-citation></ref><ref id="cit0066"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleyzer</surname><given-names>N</given-names></name><name><surname>Scarpulla</surname><given-names>RC</given-names></name></person-group><article-title>Activation of a PGC-1-related coactivator (PRC)-dependent inflammatory stress program linked to apoptosis and premature senescence</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>8004</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">23364789</pub-id></element-citation></ref><ref id="cit0067"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Abnormal mitochondrial dynamics and impaired mitochondrial biogenesis in trigeminal ganglion neurons in a rat model of migraine</article-title><source>Neurosci Lett</source><year>2017</year><volume>636</volume><fpage>127</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">27984195</pub-id></element-citation></ref><ref id="cit0068"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>CF</given-names></name><name><surname>Sutherland</surname><given-names>HG</given-names></name><name><surname>Griffiths</surname><given-names>LR</given-names></name></person-group><article-title>Studies on the pathophysiology and genetic basis of migraine</article-title><source>Curr Genomics</source><year>2013</year><volume>14</volume><fpage>300</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">24403849</pub-id></element-citation></ref><ref id="cit0069"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnila</surname><given-names>S</given-names></name><name><surname>Autere</surname><given-names>J</given-names></name><name><surname>Lehtovirta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Increased risk of sensorineural hearing loss and migraine in patients with a rare mitochondrial DNA variant 4336A&#x0003e;G in tRNAGln</article-title><source>J Med Genet</source><year>2001</year><volume>38</volume><fpage>400</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11424923</pub-id></element-citation></ref><ref id="cit0070"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome</article-title><source>Am J Med Genet A</source><year>2004</year><volume>131</volume><fpage>50</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15368478</pub-id></element-citation></ref><ref id="cit0071"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>EA</given-names></name><name><surname>Freilinger</surname><given-names>T</given-names></name><name><surname>Klopstock</surname><given-names>T</given-names></name><etal/></person-group><article-title>Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome</article-title><source>Cephalalgia</source><year>2009</year><volume>29</volume><fpage>719</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19220304</pub-id></element-citation></ref><ref id="cit0072"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Esserlind</surname><given-names>AL</given-names></name><name><surname>Andersson</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Prevalence of migraine in persons with the 3243A&#x0003e;G mutation in mitochondrial DNA</article-title><source>Eur J Neurol</source><year>2016</year><volume>23</volume><fpage>175</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26435168</pub-id></element-citation></ref><ref id="cit0073"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshima</surname><given-names>T</given-names></name><name><surname>Fukuhara</surname><given-names>Y</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Leukocyte mitochondrial DNA A to G polymorphism at 11084 is not a risk factor for Japanese migraineurs</article-title><source>Cephalalgia</source><year>2001</year><volume>21</volume><fpage>987</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11843871</pub-id></element-citation></ref><ref id="cit0074"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>MB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Norby</surname><given-names>S</given-names></name></person-group><article-title>Genetic heterogeneity of migraine with and without aura in Danes cannot be explained by mutation in mtDNA nucleotide pair 11084</article-title><source>Acta Neurol Scand</source><year>1997</year><volume>96</volume><fpage>171</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9300071</pub-id></element-citation></ref><ref id="cit0075"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimomura</surname><given-names>TKA</given-names></name><name><surname>Marukawa</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Mutation in platelet mitochondrial gene in patients with migraine</article-title><source>Cephalalgia</source><year>1995</year><volume>15</volume><fpage>10</fpage><pub-id pub-id-type="pmid">8749240</pub-id></element-citation></ref><ref id="cit0076"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparaco</surname><given-names>M</given-names></name><name><surname>Feleppa</surname><given-names>M</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Rapoport</surname><given-names>AM</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name></person-group><article-title>Mitochondrial dysfunction and migraine: evidence and hypotheses</article-title><source>Cephalalgia</source><year>2006</year><volume>26</volume><fpage>361</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16556237</pub-id></element-citation></ref><ref id="cit0077"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnila</surname><given-names>S</given-names></name><name><surname>Hassinen</surname><given-names>IE</given-names></name><name><surname>Majamaa</surname><given-names>K</given-names></name></person-group><article-title>Phylogenetic analysis of mitochondrial DNA in patients with an occipital stroke. Evaluation of mutations by using sequence data on the entire coding region</article-title><source>Mutat Res</source><year>2001</year><volume>458</volume><fpage>31</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11406419</pub-id></element-citation></ref><ref id="cit0078"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcuello</surname><given-names>A</given-names></name><name><surname>Martinez-Redondo</surname><given-names>D</given-names></name><name><surname>Dahmani</surname><given-names>Y</given-names></name></person-group><article-title>Human mitochondrial variants influence on oxygen consumption</article-title><source>Mitochondrion</source><year>2009</year><volume>9</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18952007</pub-id></element-citation></ref><ref id="cit0079"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies</article-title><source>Hematology Am Soc Hematol Educ Program</source><year>2017</year><volume>2017</volume><fpage>518</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">29222300</pub-id></element-citation></ref><ref id="cit0080"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MH</given-names></name><name><surname>Moos</surname><given-names>WH</given-names></name><name><surname>Faller</surname><given-names>DV</given-names></name><name><surname>Steliou</surname><given-names>K</given-names></name><name><surname>Pinkert</surname><given-names>CA</given-names></name></person-group><article-title>Epigenetic treatment of neurodegenerative disorders: Alzheimer and Parkinson diseases</article-title><source>Drug Dev Res</source><year>2016</year><volume>77</volume><fpage>109</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26899010</pub-id></element-citation></ref><ref id="cit0081"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>N</given-names></name><name><surname>Tavakoli</surname><given-names>M</given-names></name><name><surname>Charati</surname><given-names>JY</given-names></name><name><surname>Shamsizade</surname><given-names>M</given-names></name></person-group><article-title>Single-dose intravenous sodium valproate (Depakine) versus dexamethasone for the treatment of acute migraine headache: a double-blind randomized clinical trial</article-title><source>Clin Exp Emerg Med</source><year>2017</year><volume>4</volume><fpage>138</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">29026887</pub-id></element-citation></ref><ref id="cit0082"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Che</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine</article-title><source>Front Neurol</source><year>2017</year><volume>8</volume><fpage>524</fpage><pub-id pub-id-type="pmid">29075232</pub-id></element-citation></ref><ref id="cit0083"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Valproate plays a protective role against migraine by inhibiting protein kinase C signalling in nitroglycerin-treated mice</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2018</year><volume>122</volume><fpage>310</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">28990289</pub-id></element-citation></ref><ref id="cit0084"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunder</surname><given-names>SK</given-names></name><name><surname>Bairy</surname><given-names>LK</given-names></name><name><surname>Arivazhahan</surname><given-names>A</given-names></name></person-group><article-title>Effect of sodium valproate and docosahexaenoic acid on pain in rats</article-title><source>J Clin Diagn Res</source><year>2017</year><volume>11</volume><fpage>FF05</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">28511406</pub-id></element-citation></ref><ref id="cit0085"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>HL</given-names></name><name><surname>Shi</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>XP</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name></person-group><article-title>The pharmacogenomics of valproic acid</article-title><source>J Hum Genet</source><year>2017</year><volume>62</volume><fpage>1009</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">28878340</pub-id></element-citation></ref><ref id="cit0086"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passaro</surname><given-names>D</given-names></name><name><surname>Rana</surname><given-names>G</given-names></name><name><surname>Piscopo</surname><given-names>M</given-names></name><name><surname>Viggiano</surname><given-names>E</given-names></name><name><surname>De Luca</surname><given-names>B</given-names></name><name><surname>Fucci</surname><given-names>L</given-names></name></person-group><article-title>Epigenetic chromatin modifications in the cortical spreading depression</article-title><source>Brain Res</source><year>2010</year><volume>1329</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20211609</pub-id></element-citation></ref><ref id="cit0087"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JU</given-names></name><name><surname>Ma</surname><given-names>DK</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neuronal activity modifies the DNA methylation landscape in the adult brain</article-title><source>Nat Neurosci</source><year>2011</year><volume>14</volume><fpage>1345</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21874013</pub-id></element-citation></ref><ref id="cit0088"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rana</surname><given-names>G</given-names></name><name><surname>Donizetti</surname><given-names>A</given-names></name><name><surname>Virelli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cortical spreading depression differentially affects lysine methylation of H3 histone at neuroprotective genes and retrotransposon sequences</article-title><source>Brain Res</source><year>2012</year><volume>1467</volume><fpage>113</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22659026</pub-id></element-citation></ref><ref id="cit0089"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerring</surname><given-names>ZF</given-names></name><name><surname>McRae</surname><given-names>AF</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Nyholt</surname><given-names>DR</given-names></name></person-group><article-title>Genome-wide DNA methylation profiling in whole blood reveals epigenetic signatures associated with migraine</article-title><source>BMC Genomics</source><year>2018</year><volume>19</volume><fpage>69</fpage><pub-id pub-id-type="pmid">29357833</pub-id></element-citation></ref><ref id="cit0090"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Wijst</surname><given-names>MG</given-names></name><name><surname>Rots</surname><given-names>MG</given-names></name></person-group><article-title>Mitochondrial epigenetics: an overlooked layer of regulation?</article-title><source>Trends Genet</source><year>2015</year><volume>31</volume><fpage>353</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25891224</pub-id></element-citation></ref><ref id="cit0091"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okano</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Li</surname><given-names>E</given-names></name></person-group><article-title>DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development</article-title><source>Cell</source><year>1999</year><volume>99</volume><fpage>247</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10555141</pub-id></element-citation></ref><ref id="cit0092"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollefsbol</surname><given-names>TO</given-names></name><name><surname>Hutchison</surname><given-names>CA 3rd</given-names></name></person-group><article-title>Analysis in Escherichia coli of the effects of in vivo CpG methylation catalyzed by the cloned murine maintenance methyltransferase</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>245</volume><fpage>670</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9588173</pub-id></element-citation></ref><ref id="cit0093"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><article-title>Mitochondrial DNA: impacting central and peripheral nervous systems</article-title><source>Neuron</source><year>2014</year><volume>84</volume><fpage>1126</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">25521375</pub-id></element-citation></ref><ref id="cit0094"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shock</surname><given-names>LS</given-names></name><name><surname>Thakkar</surname><given-names>PV</given-names></name><name><surname>Peterson</surname><given-names>EJ</given-names></name><name><surname>Moran</surname><given-names>RG</given-names></name><name><surname>Taylor</surname><given-names>SM</given-names></name></person-group><article-title>DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>3630</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21321201</pub-id></element-citation></ref><ref id="cit0095"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>SK</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Bernstein</surname><given-names>E</given-names></name><etal/></person-group><article-title>DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>714</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17687327</pub-id></element-citation></ref><ref id="cit0096"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Gertz</surname><given-names>B</given-names></name><name><surname>Chestnut</surname><given-names>BA</given-names></name><name><surname>Martin</surname><given-names>LJ</given-names></name></person-group><article-title>Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS</article-title><source>Front Cell Neurosci</source><year>2013</year><volume>7</volume><fpage>279</fpage><pub-id pub-id-type="pmid">24399935</pub-id></element-citation></ref><ref id="cit0097"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaughnessy</surname><given-names>DT</given-names></name><name><surname>McAllister</surname><given-names>K</given-names></name><name><surname>Worth</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mitochondria, energetics, epigenetics, and cellular responses to stress</article-title><source>Environ Health Perspect</source><year>2014</year><volume>122</volume><fpage>1271</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25127496</pub-id></element-citation></ref><ref id="cit0098"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzitoyeva</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Manev</surname><given-names>H</given-names></name></person-group><article-title>Effect of aging on 5-hydroxymethylcytosine in brain mitochondria</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>2881</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">22445327</pub-id></element-citation></ref><ref id="cit0099"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirola</surname><given-names>CJ</given-names></name><name><surname>Scian</surname><given-names>R</given-names></name><name><surname>Gianotti</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Epigenetic modifications in the biology of nonalcoholic fatty liver disease: the role of DNA hydroxymethylation and TET proteins</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><fpage>e1480</fpage><pub-id pub-id-type="pmid">26356709</pub-id></element-citation></ref><ref id="cit0100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salminen</surname><given-names>A</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Kauppinen</surname><given-names>A</given-names></name></person-group><article-title>Krebs cycle dysfunction shapes epigenetic landscape of chromatIn: novel insights into mitochondrial regulation of aging process</article-title><source>Cell Signal</source><year>2014</year><volume>26</volume><fpage>1598</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">24704120</pub-id></element-citation></ref><ref id="cit0101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veeranki</surname><given-names>S</given-names></name><name><surname>Winchester</surname><given-names>LJ</given-names></name><name><surname>Tyagi</surname><given-names>SC</given-names></name></person-group><article-title>Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications</article-title><source>Biochim Biophys Acta</source><year>2015</year><volume>1852</volume><fpage>732</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">25615794</pub-id></element-citation></ref><ref id="cit0102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VS</given-names></name><name><surname>Langley</surname><given-names>B</given-names></name></person-group><article-title>Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy</article-title><source>Neurosci Lett</source><year>2016</year><volume>625</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">27155457</pub-id></element-citation></ref><ref id="cit0103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechta</surname><given-names>M</given-names></name><name><surname>Ingerslev</surname><given-names>LR</given-names></name><name><surname>Fabre</surname><given-names>O</given-names></name><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Barres</surname><given-names>R</given-names></name></person-group><article-title>Evidence suggesting absence of mitochondrial DNA methylation</article-title><source>Front Genet</source><year>2017</year><volume>8</volume><fpage>166</fpage><pub-id pub-id-type="pmid">29163634</pub-id></element-citation></ref><ref id="cit0104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Hsu</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer</article-title><source>Am J Transl Res</source><year>2012</year><volume>4</volume><fpage>127</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">22611467</pub-id></element-citation></ref><ref id="cit0105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillar</surname><given-names>N</given-names></name><name><surname>Bairey</surname><given-names>O</given-names></name><name><surname>Goldschmidt</surname><given-names>N</given-names></name><etal/></person-group><article-title>MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>86020</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">29156774</pub-id></element-citation></ref><ref id="cit0106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leggio</surname><given-names>L</given-names></name><name><surname>Vivarelli</surname><given-names>S</given-names></name><name><surname>L&#x02019;Episcopo</surname><given-names>F</given-names></name><etal/></person-group><article-title>microRNAs in Parkinson&#x02019;s disease: from pathogenesis to novel diagnostic and therapeutic approaches</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><fpage>E2698</fpage><pub-id pub-id-type="pmid">29236052</pub-id></element-citation></ref><ref id="cit0107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandiera</surname><given-names>S</given-names></name><name><surname>Ruberg</surname><given-names>S</given-names></name><name><surname>Girard</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nuclear outsourcing of RNA interference components to human mitochondria</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e20746</fpage><pub-id pub-id-type="pmid">21695135</pub-id></element-citation></ref><ref id="cit0108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plath</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Mlynarczyk-Evans</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Role of histone H3 lysine 27 methylation in X inactivation</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>131</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12649488</pub-id></element-citation></ref><ref id="cit0109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>W</given-names></name></person-group><article-title>Up-regulation of the long non-coding RNA RMRP contributes to glioma progression and promotes glioma cell proliferation and invasion</article-title><source>Arch Med Sci</source><year>2017</year><volume>13</volume><fpage>1315</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">29181061</pub-id></element-citation></ref><ref id="cit0110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Si</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><article-title>Identification of differentially expressed profiles of lncRNAs and mRNAs in ER-negative and HER-2 positive breast cancer</article-title><source>Arch Med Sci Civil Dis</source><year>2017</year><volume>2</volume><fpage>e148</fpage><lpage>60</lpage></element-citation></ref><ref id="cit0111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Neph</surname><given-names>S</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><etal/></person-group><article-title>The human mitochondrial transcriptome</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>645</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">21854988</pub-id></element-citation></ref><ref id="cit0112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Yoshitomi</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>JF</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>Long noncoding RNAs coordinate functions between mitochondria and the nucleus</article-title><source>Epigenetics Chromatin</source><year>2017</year><volume>10</volume><fpage>41</fpage><pub-id pub-id-type="pmid">28835257</pub-id></element-citation></ref><ref id="cit0113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Abdelmohsen</surname><given-names>K</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name></person-group><article-title>Functional interactions among microRNAs and long noncoding RNAs</article-title><source>Semin Cell Dev Biol</source><year>2014</year><volume>34</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">24965208</pub-id></element-citation></ref><ref id="cit0114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayoumi</surname><given-names>AS</given-names></name><name><surname>Sayed</surname><given-names>A</given-names></name><name><surname>Broskova</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Crosstalk between long noncoding RNAs and microRNAs in health and disease</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume><fpage>356</fpage><pub-id pub-id-type="pmid">26978351</pub-id></element-citation></ref><ref id="cit0115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>YN</given-names></name><name><surname>Ren</surname><given-names>ZR</given-names></name><name><surname>Yan</surname><given-names>JB</given-names></name></person-group><article-title>Dysfunctions of mitochondria in close association with strong perturbation of long noncoding RNAs expression in down syndrome</article-title><source>Int J Biochem Cell Biol</source><year>2017</year><volume>92</volume><fpage>115</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28965985</pub-id></element-citation></ref><ref id="cit0116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matilainen</surname><given-names>O</given-names></name><name><surname>Quiros</surname><given-names>PM</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Mitochondria and epigenetics &#x02013; crosstalk in homeostasis and stress</article-title><source>Trends Cell Biol</source><year>2017</year><volume>27</volume><fpage>453</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28274652</pub-id></element-citation></ref><ref id="cit0117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SP</given-names></name><name><surname>Fuh</surname><given-names>JL</given-names></name><name><surname>Chung</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies novel susceptibility loci for migraine in Han Chinese resided in Taiwan</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>466</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">28952330</pub-id></element-citation></ref><ref id="cit0118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winsvold</surname><given-names>BS</given-names></name><name><surname>Bettella</surname><given-names>F</given-names></name><name><surname>Witoelar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Shared genetic risk between migraine and coronary artery disease: a genome-wide analysis of common variants</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0185663</fpage><pub-id pub-id-type="pmid">28957430</pub-id></element-citation></ref><ref id="cit0119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eising</surname><given-names>E</given-names></name><name><surname>Datson</surname><given-names>NA</given-names></name><name><surname>van den Maagdenberg</surname><given-names>AM</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name></person-group><article-title>Epigenetic mechanisms in migraine: a promising avenue?</article-title><source>BMC Med</source><year>2013</year><volume>11</volume><fpage>26</fpage><pub-id pub-id-type="pmid">23379668</pub-id></element-citation></ref><ref id="cit0120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dykes</surname><given-names>IM</given-names></name><name><surname>Emanueli</surname><given-names>C</given-names></name></person-group><article-title>Transcriptional and post-transcriptional gene regulation by long non-coding RNA</article-title><source>Genomics Proteomics Bioinformatics</source><year>2017</year><volume>15</volume><fpage>177</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">28529100</pub-id></element-citation></ref><ref id="cit0121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name></person-group><article-title>Epitranscriptomics: toward a better understanding of RNA modifications</article-title><source>Genomics Proteomics Bioinformatics</source><year>2017</year><volume>15</volume><fpage>147</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">28533024</pub-id></element-citation></ref><ref id="cit0122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashrafi</surname><given-names>G</given-names></name><name><surname>Schwarz</surname><given-names>TL</given-names></name></person-group><article-title>The pathways of mitophagy for quality control and clearance of mitochondria</article-title><source>Cell Death Differ</source><year>2013</year><volume>20</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22743996</pub-id></element-citation></ref><ref id="cit0123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobazzi</surname><given-names>V</given-names></name><name><surname>Castegna</surname><given-names>A</given-names></name><name><surname>Infantino</surname><given-names>V</given-names></name><name><surname>Andria</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool</article-title><source>Mol Genet Metab</source><year>2013</year><volume>110</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">23920043</pub-id></element-citation></ref></ref-list></back></article>